Xueyan Wu

Dr. Xueyan Wu


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
JZJunjie Zheng
Junjie Zheng
JMJiangfeng Mao
Jiangfeng Mao
MCMingxuan Cui
Mingxuan Cui
ZLZhaoxiang Liu
Zhaoxiang Liu
XWXi Wang
Xi Wang
XWXueyan Wu
Xueyan Wu

1 March 2016 in Medicine
Verified
Journal Article
Open access
ZLZhaoxiang Liu
Zhaoxiang Liu
JMJangfeng Mao
Jangfeng Mao
XWXueyan Wu
Xueyan Wu
HXHongli Xu
Hongli Xu
XWXi Wang
Xi Wang
HZHongbing Zhang
Hongbing Zhang
Gonadotropin induces masculinization and spermatogenesis in men with congenital hypogonadotropic hypogonadism (CHH). However, large cohort studies for the efficacy and reliable predictors of this therapy need to be conducted. The aim of this study was to investigate the efficacy of gonadotropin treatment in a large cohort of male CHH patients and analyze putative predictors for successful spermatogenesis. This retrospective study included 223 CHH azoospermic patients without puberty development treated between 2005 and 2014. All patients received combined human chorionic gonadotropin (HCG) and human menopausal gonadotropin (HMG) and were followed up for >6 months (5109 person-months). Serum total testosterone level, testicular size, spermatogenesis, and pregnancy outcome were recorded at each visit. After gonadotropin therapy, testicular size was enlarged from 2.1 ± 1.6 to 8.1 ± 4.6 mL (P < 0.001) and serum total testosterone was elevated from 0.9 ± 0.5 to 15.1 ± 8.2 nmol/L (P < 0.001). Spermatogenesis (>0/mL) occurred at a median period of 15 months (95% confidence interval 13.5-16.5). Larger basal testicular volume (P = 0.012) and noncryptorchidism history (P = 0.028) are independent predictors for earlier sperm appearance. Sixty four percent (143/223) of patients succeeded in producing sperms and the average time for initial sperm detection was 14 ± 8 months. However, their sperm concentrations (11.7 [2.1, 24.4] million/mL) and sperm progressive motility (A + B 36.9% ± 20.2%) are significantly lower than World Health Organization standards. Of the 34 patients who desired for fathering children, 19 patients impregnanted their partners during the treatment. Gonadotropin therapy induces spermatogenesis in male CHH patients. A larger basal testicular size and noncryptorchidism history are favorable indicators for earlier spermatogenesis.

1 January 2017 in Asian Journal of Andrology
Verified
Journal Article
Open access
PDF file
XWXueyan Wu
Xueyan Wu
JMJiang-Feng Mao
Jiang-Feng Mao
ZLZhao-Xiang Liu
Zhao-Xiang Liu
MNMin Nie
Min Nie
XWXi Wang
Xi Wang
UKUrsulaBrigitte Kaiser
UrsulaBrigitte Kaiser
Both pulsatile gonadotropin-releasing hormone (GnRH) infusion and combined gonadotropin therapy (human chorionic gonadotropin and human menopausal gonadotropin [HCG/HMG]) are effective to induce spermatogenesis in male patients with congenital hypogonadotropic hypogonadism (CHH). However, evidence is lacking as to which treatment strategy is better. This retrospective cohort study included 202 patients with CHH: twenty had received pulsatile GnRH and 182 had received HCG/HMG. Patients had received therapy for at least 12 months. The total follow-up time was 15.6 ± 5.0 months (range: 12-27 months) for the GnRH group and 28.7 ± 13.0 months (range: 12-66 months) for the HCG/HMG group. The median time to first sperm appearance was 6 months (95% confidence interval [CI]: 1.6-10.4) in the GnRH group versus 18 months (95% CI: 16.4-20.0) in the HCG/HMG group (P < 0.001). The median time to achieve sperm concentrations ≥5 × 10 6 ml−1 was 14 months (95% CI: 5.8-22.2) in the GnRH group versus 27 months (95% CI: 18.9-35.1) in the HCG/HMG group (P < 0.001), and the median time to concentrations ≥10 × 10 6 ml−1 was 18 months (95% CI: 10.0-26.0) in the GnRH group versus 39 months (95% CI unknown) in the HCG/HMG group. Compared to the GnRH group, the HCG/HMG group required longer treatment periods to achieve testicular sizes of ≥4 ml, ≥8 ml, ≥12 ml, and ≥16 ml. Sperm motility (a + b + c percentage) evaluated in semen samples with concentrations >1 × 10 6 ml−1 was 43.7% ± 20.4% (16 samples) in the GnRH group versus 43.2% ± 18.1% (153 samples) in the HCG/HMG group (P = 0.921). Notably, during follow-up, the GnRH group had lower serum testosterone levels than the HCG/HMG group (8.3 ± 4.6 vs 16.2 ± 8.2 nmol l−1 , P < 0.001). Our study found that pulsatile GnRH therapy was associated with earlier spermatogenesis and larger testicular size compared to combined gonadotropin therapy. Additional prospective randomized studies would be required to confirm these findings.

24 August 2010 in Molecular Human Reproduction
Verified
Journal Article
Open access
PDF file
MNMin Nie
Min Nie
QZQ. Zhou
Q. Zhou
JMJiangfeng Mao
Jiangfeng Mao
SLShuangyu Lu
Shuangyu Lu
XWXueyan Wu
Xueyan Wu
Individuals with male karyotype (46,XY) affected by 5α-reductase type 2 deficiency, a rare autosomal recessive inherited disorder, can have an almost female phenotype or partially virilized external genitalia. Mutations in the steroid-5-α-reductase (SRD5A2) gene, leading to functional impairment of 5α-reductase type 2, are responsible for this disorder. Our present study analyzed SRD5A2 gene mutations in eight unrelated 46,XY Chinese patients with disorders of sex development. Direct sequencing of genomic DNA for SRD5A2 gene revealed the presence of one homozygous (p.Q6X) and seven compound heterozygous mutations (p.G203S/R227Q, p.L20P/R227Q, p.Q6X/p.A228V, p.C222Ffs232X/p.R246Q, p.W140X/F219Sfs278X, p.Q71X/L185Tfs192X and p.Q6X/p.N193S) in our patients. Among them, p.C222Ffs232X, p.A228V, p.Q71X, L185Tfs192X and p.W140X mutations have not been previously reported. These novel mutations may provide us new insights into the molecular mechanism of 5α-reductase type 2 deficiency. Seven out of eight patients had at least one variant in exon 4, and 8 of 12 (66.7%) mutations were located in exon 4. The expanded mutation database of the SRD5A2 gene should benefit patients in the diagnosis and treatment of this disease.

1 January 2015 in Asian Journal of Andrology
Verified
Journal Article
Open access
XWXueyan Wu
Xueyan Wu
JMJiang-Feng Mao
Jiang-Feng Mao
HXHong-Li Xu
Hong-Li Xu
JDJin Duan
Jin Duan
RCRong-Rong Chen
Rong-Rong Chen
HZHong-Bing Zhang
Hong-Bing Zhang
Although idiopathic hypogonadotropic hypogonadism (IHH) has traditionally been viewed as a life-long disease caused by a deficiency of gonadotropin-releasing hormone neurons, a portion of patients may gradually regain normal reproductive axis function during hormonal replacement therapy. The predictive factors for potential IHH reversal are largely unknown. The aim of our study was to investigate the incidence and clinical features of IHH male patients who had reversed reproductive axis function. In this retrospective cohort study, male IHH patients were classified into a reversal group (n = 18) and a nonreversal group (n = 336). Concentration of gonadotropins and testosterone, as well as testicle sizes and sperm counts, were determined. Of 354 IHH patients, 18 (5.1%) acquired normal reproductive function during treatment. The median age for reversal was 24 years old (range 21-34 years). Compared with the nonreversal group, the reversible group had higher basal luteinizing hormone (LH) (1.0 ± 0.7 IU l -[1] vs 0.4 ± 0.4 IU l-1 , P< 0.05) and stimulated LH (28.3 ± 22.6 IU l-1 vs 1.9 ± 1.1 IU l-1 , P< 0.01) levels, as well as larger testicle size (5.1 ± 2.6 ml vs 1.5 ± 0.3 ml, P< 0.01), at the initial visit. In summary, larger testicle size and higher stimulated LH concentrations are favorite parameters for reversal. Our finding suggests that reversible patients may retain partially active reproductive axis function at initial diagnosis.

15 April 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
YGYinjie Gao
Yinjie Gao
LLLin Lu
Lin Lu
BYBingqing Yu
Bingqing Yu
JMJiangfeng Mao
Jiangfeng Mao
XWXi Wang
Xi Wang
XWXueyan Wu
Xueyan Wu
Purpose Defects in both CYP21A2 and TNXB genes can cause congenital adrenal hyperplasia combined with hypermobility type Ehlers-Danlos syndrome, which has recently been named CAH-X syndrome. The purpose of this study is to assess the prevalence of chimeric TNXA/TNXB gene and clinical symptoms in a Chinese cohort with 21-hydroxylase deficiency (21-OHD). Methods A total of 424 patients with 21-OHD who were genetically diagnosed were recruited for this study. Multiplex ligation dependent probe amplification and sequencing were used to identify the CAH-X genotype. Clinical features of joints, skin, and others systems were evaluated in 125 patients. Results Here, 94 of the 424 patients had a deletion on at least one allele of CYP21A2 and 59 of them harbored heterozygotic TNXA/TNXB chimera. Frequencies of CAH-X CH-1, CH-2, and CH-3 were 8.2%, 3.1%, and 2.6%, respectively. The incidences of clinical features of EDS were 71.0% and 26.6% in patients with chimeric TNXA/TNXB genes or without (p<0.001). There were statistically significant differences in manifestations among the articular (p<0.001 in generalized hypermobility) and dermatologic (p<0.001 in hyperextensible skin, p=0.015 in velvety skin and p=0.033 in poor wound healing). The prevalence of generalized hypermobility was more common in CAH-X CH-2 or CH-3 than CH-1 patients (60% vs 20%, P=0.028). Conclusions In summary, about 14% of patients with 21-OHD may have chimeric TNXA/TNXB gene mutations in our study and most of them showed EDS related clinical symptoms. The correlation between CAH-X genotypes and clinical features in connective tissue like joint or skin needs to be further investigated.